{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:43:28Z","timestamp":1787013808156,"version":"build-2736575974"},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Global studies have demonstrated the efficacy and safety of blinatumomab\u2014a BiTE\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (bispecific T\u2010cell engager) targeted immuno\u2010oncology therapy that mediates the lysis of cells expressing CD19 in patients with relapsed\/refractory acute lymphoblastic leukemia (R\/R ALL). Because limited data are available in Asian patients, we conducted a post hoc pooled analysis in 45 Asian adult patients with R\/R ALL\u201419 from the blinatumomab arm of TOWER (NCT02013167) and 26 from Study 265, a phase 1b\/2 study in Japanese adults (NCT02412306).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients received a maximum of two cycles of induction blinatumomab for 4\u00a0weeks by continuous intravenous infusion (cycle 1\/week 1: 9 \u03bcg\/day; cycle 1\/weeks 2\u20134: 28 \u03bcg\/day) followed by 2\u00a0weeks of no blinatumomab (each 6\u2010week cycle); patients received 28 \u03bcg\/day blinatumomab in subsequent cycles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty of 45 patients enrolled (44%) achieved complete remission with full or partial hematologic recovery compared with 44% in TOWER and 80% and 38% in phase 1b and phase 2, respectively, of Study 265. The Kaplan\u2013Meier (KM) median overall survival was 11.9 months (95% confidence interval [CI], 9.9\u201317.1) and the KM median duration of relapse\u2010free survival was 8.9 months (95% CI, 3.8\u201310.7). Ninety\u2010three percent of patients had grade \u2265 3 treatment\u2010emergent adverse events (AEs) compared with 87% in TOWER and 80% and 100% in phase 1b and phase 2, respectively, of Study 265. Five patients (11.4%) had fatal AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The safety and efficacy of blinatumomab in Asian patients were comparable with those reported in previous global studies with no new safety signals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajco.13609","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T15:40:21Z","timestamp":1624981221000},"page":"311-318","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed\/refractory B\u2010cell precursor acute lymphoblastic leukemia"],"prefix":"10.1111","volume":"18","author":[{"given":"Yukio","family":"Kobayashi","sequence":"first","affiliation":[{"name":"National Cancer Center Hospital  Tokyo Japan"},{"name":"International University of Health and Welfare, Mita Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iekuni","family":"Oh","sequence":"additional","affiliation":[{"name":"Jichi Medical University  Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science Kyushu University Graduate School of Medical Science  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won\u2010Sik","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hemato\u2010Oncology, Busan Paik Hospital Inje University  Busan Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroatsu","family":"Iida","sequence":"additional","affiliation":[{"name":"National Hospital Organization Nagoya Medical Center  Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[{"name":"Medical Oncology\/Hematology Kobe University Graduate School of Medicine and Hospital  Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Okayama University Hospital  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Ho","family":"Jang","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology Samsung Medical Center, Sungkyunkwan University College of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung\u2010Soo","family":"Yoon","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Medical Oncology, Department of Internal Medicine Seoul National University Hospital, Seoul National University College of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su\u2010Peng","family":"Yeh","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine China Medical University Hospital  Taichung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qui","family":"Tran","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6267-7637","authenticated-orcid":false,"given":"Joan","family":"Morris","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Franklin","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Nagoya University Graduate School of Medicine  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70452-2"},{"issue":"5","key":"e_1_2_12_3_1","first-page":"1","article-title":"Global incidence and prevalence of acute lymphoblastic leukemia: A 10\u2010year forecast","volume":"8","author":"Solomon B","year":"2017","journal-title":"J Blood Disord Transfus"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144311"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23919"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25354"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402890"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10557"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20908"},{"key":"e_1_2_12_14_1","unstructured":"BLINCYTO\u00aePrescribing Information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125557s013lbl.pdf. Accessed May 19 2021."},{"key":"e_1_2_12_15_1","unstructured":"Amgen press release.https:\/\/www.amgen.com\/media\/news\u2010releases\/2018\/09\/blincyto\u2010blinatumomab\u2010approved\u2010in\u2010japan\u2010for\u2010the\u2010treatment\u2010of\u2010relapsed\u2010or\u2010refractory\u2010bcell\u2010acute\u2010lymphoblastic\u2010leukemia\/. Accessed May 19 2021."},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14322"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13609","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.13609","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T19:47:25Z","timestamp":1692820045000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/ajco.13609"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13609","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]},"assertion":[{"value":"2021-03-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}